Zealand Pharma major shareholder announcement: Van Herk Investments
28 juin 2024 11h10 HE
|
Zealand Pharma
Company announcement – No. 38 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 28 June 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...
Total number of shares and voting rights in Zealand Pharma at June 28, 2024
28 juin 2024 11h05 HE
|
Zealand Pharma
Company announcement – No. 37 / 2024 Total number of shares and voting rights in Zealand Pharma at June 28, 2024 Copenhagen, Denmark, June 28, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ:...
Zealand Pharma completes registration of capital increase
28 juin 2024 02h36 HE
|
Zealand Pharma
Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...
Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion
25 juin 2024 18h35 HE
|
Zealand Pharma
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion...
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
25 juin 2024 14h43 HE
|
Zealand Pharma
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7...
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
25 juin 2024 11h02 HE
|
Zealand Pharma
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR...
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
20 juin 2024 11h37 HE
|
Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
13 juin 2024 11h00 HE
|
Zealand Pharma
Company announcement – No. 31 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 13, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07 juin 2024 04h38 HE
|
Zealand Pharma
Company announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of...
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
06 juin 2024 06h29 HE
|
Zealand Pharma
Company announcement - No. 29 / 2024 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL Copenhagen, Denmark,...